Literature DB >> 14570276

Neomycin and paromomycin inhibit 30S ribosomal subunit assembly in Staphylococcus aureus.

Roopal Mehta1, W Scott Champney.   

Abstract

A number of different antibiotics that prevent translation by binding to the 50S ribosomal subunit of bacterial cells have recently been shown to also prevent assembly of this subunit. Antibacterial agents affecting 30S particle activities have not been examined extensively for effects on small subunit formation. The aminoglycoside antibiotics paromomycin and neomycin bind specifically to the 30S ribosomal subunit and inhibit translation. These drugs were examined in Staphylococcus aureus cells to see whether they had a second inhibitory effect on 30S particle assembly. A 3H-uridine pulse and chase assay was used to examine the kinetics of subunit synthesis in the presence and absence of each antibiotic. 30S subunit formation was inhibited by both compounds. At 3 microg/mL each antibiotic reduced the rate of 30S formation by 80% compared with control cells. Both antibiotics showed a concentration-dependent inhibition of particle formation, with a lesser effect on 50S particle formation. For neomycin, the IC50 for 30S particle formation was equal to the IC50 for inhibition of translation. Both antibiotics reduced the viable cell number with an IC50 of 2 microg/mL. They also inhibited protein synthesis in the cells with different IC50 values (2.5 and 1.25 microg/mL). This is the second demonstration of 30S ribosomal subunit-specific antibiotics that prevent assembly of the small subunit.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14570276     DOI: 10.1007/s00284-002-3945-9

Source DB:  PubMed          Journal:  Curr Microbiol        ISSN: 0343-8651            Impact factor:   2.188


  18 in total

1.  The vanadyl ribonucleoside complex inhibits ribosomal subunit formation in Staphylococcus aureus.

Authors:  Ashley D Frazier; W Scott Champney
Journal:  J Antimicrob Chemother       Date:  2012-05-29       Impact factor: 5.790

Review 2.  Inhibition of bacterial ribosome assembly: a suitable drug target?

Authors:  Bruce A Maguire
Journal:  Microbiol Mol Biol Rev       Date:  2009-03       Impact factor: 11.056

3.  Spatially segregated transcription and translation in cells of the endomembrane-containing bacterium Gemmata obscuriglobus.

Authors:  Ekaterina Y Gottshall; Corrine Seebart; Jesse C Gatlin; Naomi L Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-14       Impact factor: 11.205

4.  Hygromycin B inhibition of protein synthesis and ribosome biogenesis in Escherichia coli.

Authors:  Susan M McGaha; W Scott Champney
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

5.  Impairment of ribosomal subunit synthesis in aminoglycoside-treated ribonuclease mutants of Escherichia coli.

Authors:  Ashley D Frazier; W S Champney
Journal:  Arch Microbiol       Date:  2012-08-29       Impact factor: 2.552

Review 6.  Aminoglycoside modifying enzymes.

Authors:  Maria S Ramirez; Marcelo E Tolmasky
Journal:  Drug Resist Updat       Date:  2010-09-15       Impact factor: 18.500

7.  Mutational biosynthesis of neomycin analogs by a mutant of neomycin-producing Streptomyces fradiae.

Authors:  Guanying Shi; Xingang Zhang; Lang Wu; Jin Xie; Ke Tao; Taiping Hou
Journal:  Folia Microbiol (Praha)       Date:  2011-11-15       Impact factor: 2.099

8.  Quantitative proteomic analysis of ribosome assembly and turnover in vivo.

Authors:  Michael T Sykes; Zahra Shajani; Edit Sperling; Andrea H Beck; James R Williamson
Journal:  J Mol Biol       Date:  2010-08-13       Impact factor: 5.469

9.  Inhibition of ribosomal subunit synthesis in Escherichia coli by the vanadyl ribonucleoside complex.

Authors:  Ashley D Frazier; W Scott Champney
Journal:  Curr Microbiol       Date:  2013-03-20       Impact factor: 2.188

10.  Rise and dissemination of aminoglycoside resistance: the aac(6')-Ib paradigm.

Authors:  María S Ramirez; Nikolas Nikolaidis; Marcelo E Tolmasky
Journal:  Front Microbiol       Date:  2013-05-17       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.